Girish V. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Girish V. Shah has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Shibu Thomas
Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71201, United States of America
10 shared publicationsAfaf Aldahish
Pharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA
5 shared publicationsAjay Kale
Pharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209, USA
5 shared publicationsAhmed Aljameeli
Pharmacology, College of Pharmacy, University of Louisiana at Monroe, Monroe, Louisiana, USA
4 shared publicationsArvind Thakkar
Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71209, USA
4 shared publicationsKenneth A. Iczkowski
Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA
4 shared publications
Latest Publications
- RetractionOpen Access
- 20 January 2025
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66  (3) , 1
[Retracted] Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer
Following the publication of this paper, a concerned reader drew to the attention of the Editorial Office that, for the photomicrographs shown in Fig. 2B on p. 8, the same image had apparently been selected to represent the images for cerebrum and cerebellum from the brain. Secondly, the same image for the prostate tissue in Fig. 2B was used as the 'Matched normal' data in Fig. 3C on p. 9, and thirdly, the si3 and si3+CT images selected for Fig. 7B on p. 13 appeared to be derived from the same original source. Finally, after having performed an independent analysis of the data in the Editorial Office, it was noted that, for the wound healing assay data shown in Fig. 8E on p. 14, overlapping sections were identified comparing the CT and Overexp panels in the lower panel of images in this figure, such that data which were intended to show the results of differently performed experiments had apparently been derived from the same original source. After having considered these issues, owing to the number of instances of apparently misassembled data that have been identified in this paper, and also on the basis of an overall lack of confidence in the presented data, the Editor of International Journal of Oncology has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 62: 38, 2023; DOI: 10.3892/ijo.2023.5486].
- 20 January 2025
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 66  (3) , 1
RetractionOpen Access[Retracted] Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer
Following the publication of this paper, a concerned reader drew to the attention of the Editorial Office that, for the photomicrographs shown in Fig. 2B on p. 8, the same image had apparently been selected to represent the images for cerebrum and cerebellum from the brain. Secondly, the same image for the prostate tissue in Fig. 2B was used as the 'Matched normal' data in Fig. 3C on p. 9, and thirdly, the si3 and si3+CT images selected for Fig. 7B on p. 13 appeared to be derived from the same original source. Finally, after having performed an independent analysis of the data in the Editorial Office, it was noted that, for the wound healing assay data shown in Fig. 8E on p. 14, overlapping sections were identified comparing the CT and Overexp panels in the lower panel of images in this figure, such that data which were intended to show the results of differently performed experiments had apparently been derived from the same original source. After having considered these issues, owing to the number of instances of apparently misassembled data that have been identified in this paper, and also on the basis of an overall lack of confidence in the presented data, the Editor of International Journal of Oncology has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 62: 38, 2023; DOI: 10.3892/ijo.2023.5486].
- Open Access
Predicting the Diagnosis of Prostate Cancer with a Novel Blood-Based Biomarker: Comparison of Its Performance with Prostate-Specific Antigen
The purpose of this study was to assess the efficacy, specificity, and predictive value of a newly discovered biomarker, Zinc finger-like1 protein (referred to as neuroendocrine marker, NEM) for the detection of prostate cancer (PCa). We retrospectively analyzed banked plasma samples from 508 men, with a median age of 67 years (range 48–97), to compare the performance of NEM and PSA in predicting subsequent histologic PCa. The cohort consisted of four groups of patients visiting a urology clinic: (1) patients not diagnosed with either benign prostatic disease or prostate cancer (PCa) were defined as normal; (2) patients diagnosed with benign hyperplasia (BPH) but not PCa; (3) patients with confirmed PCa; and (4) patients with cancer other than PCa. The normal men displayed a mean NEM plasma level of 0.948 ± 0.051 ng/mL, which increased to 1.813 ± 0.315 ng/mL in men with BPH, 86.49 ± 15.51 ng/mL in men with PCa, and 10.47 ± 1.029 ng/mL in men with other Ca. The corresponding concentrations of prostate-specific antigen (PSA) in these subjects were 1.787 ± 0.135, 5.405 ± 0.699, 35.77 ± 11.48 ng/mL, and 8.036 ± 0.518, respectively. Receiver operating characteristic (ROC) curve analysis was performed to compare NEM and PSA performance, and the Jouden Index for each biomarker was calculated to determine cut-off points for each biomarker. The area under the ROC curve to predict PCa was 0.99 for NEM and 0.81 for PSA (p < 0.0001). The cut-off for NEM was at 1.9 ng/mL, with sensitivity of 98% and specificity of 97%. The corresponding PSA values were 4.4 ng/mL, with sensitivity of 76% and specificity of 95%. The predictive value of each biomarker in a patient was matched with his pathologic data to determine the accuracy of each biomarker. NEM was more accurate than PSA in differentiating cancer from benign conditions, such as BPH or prostatitis. In conclusion, NEM was a better predictor of PCa than PSA in patients visiting urology clinics. NEM tests, either alone or in conjunction with other biomarkers, provide a reliable, non-invasive, and inexpensive test to remarkably reduce false positives and thereby reduce the number of diagnostic biopsies and associated painful procedures and the loss of quality of life.
Open AccessPredicting the Diagnosis of Prostate Cancer with a Novel Blood-Based Biomarker: Comparison of Its Performance with Prostate-Specific Antigen
The purpose of this study was to assess the efficacy, specificity, and predictive value of a newly discovered biomarker, Zinc finger-like1 protein (referred to as neuroendocrine marker, NEM) for the detection of prostate cancer (PCa). We retrospectively analyzed banked plasma samples from 508 men, with a median age of 67 years (range 48–97), to compare the performance of NEM and PSA in predicting subsequent histologic PCa. The cohort consisted of four groups of patients visiting a urology clinic: (1) patients not diagnosed with either benign prostatic disease or prostate cancer (PCa) were defined as normal; (2) patients diagnosed with benign hyperplasia (BPH) but not PCa; (3) patients with confirmed PCa; and (4) patients with cancer other than PCa. The normal men displayed a mean NEM plasma level of 0.948 ± 0.051 ng/mL, which increased to 1.813 ± 0.315 ng/mL in men with BPH, 86.49 ± 15.51 ng/mL in men with PCa, and 10.47 ± 1.029 ng/mL in men with other Ca. The corresponding concentrations of prostate-specific antigen (PSA) in these subjects were 1.787 ± 0.135, 5.405 ± 0.699, 35.77 ± 11.48 ng/mL, and 8.036 ± 0.518, respectively. Receiver operating characteristic (ROC) curve analysis was performed to compare NEM and PSA performance, and the Jouden Index for each biomarker was calculated to determine cut-off points for each biomarker. The area under the ROC curve to predict PCa was 0.99 for NEM and 0.81 for PSA (p < 0.0001). The cut-off for NEM was at 1.9 ng/mL, with sensitivity of 98% and specificity of 97%. The corresponding PSA values were 4.4 ng/mL, with sensitivity of 76% and specificity of 95%. The predictive value of each biomarker in a patient was matched with his pathologic data to determine the accuracy of each biomarker. NEM was more accurate than PSA in differentiating cancer from benign conditions, such as BPH or prostatitis. In conclusion, NEM was a better predictor of PCa than PSA in patients visiting urology clinics. NEM tests, either alone or in conjunction with other biomarkers, provide a reliable, non-invasive, and inexpensive test to remarkably reduce false positives and thereby reduce the number of diagnostic biopsies and associated painful procedures and the loss of quality of life.
- RetractedOpen Access
- 6 February 2023
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 62  (3) , 1-20
Zinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer
Prostate‑derived calcitonin (CT) and its receptor induce tumorigenicity and increase metastatic potential of prostate cancer (PC). CT‑inducible genes in human prostate were identified by subtraction hybridization. Among these genes, zinc finger protein like 1 (ZFPL1) protein was interesting since it was abundantly expressed in malignant prostates but was almost absent in benign prostates. ZFPL1 expression was upregulated by CT and androgens, and ZFPL1 protein was secreted by prostate tumor cells through exosomal secretion. Serum levels of ZFPL1 in cancer patients were at least 4‑fold higher than those in the sera of cancer‑free individuals. Cell biology of ZFPL1 suggests its localization in Golgi bodies and exosomes, and its colocalization with chromogranin A and CD44. These results suggested that ZFPL1 is secreted by tumor cells of neuroendocrine (NE)/stem cell phenotype. The knockdown of endogenous ZFPL1 in (PC) cells led to a remarkable decrease in cell proliferation, and invasion while increasing their apoptosis. As expected, the overexpression of ZFPL1 in prostate cells had an opposite effect on these functions. The knockdown of ZFPL1 in PC cells also decreased Akt phosphorylation, suggesting the actions of ZFPL1 may be mediated through the PI3K‑Akt pathway. Moreover, the present results revealed that ZFPL1 is released by tumors cells of NE or androgen‑independent phenotype and its serum levels are significantly higher in cancer patients, suggesting that it may serve as a blood‑based non‑invasive biomarker of aggressive PC.
- 6 February 2023
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 62  (3) , 1-20
RetractedOpen AccessZinc finger protein‑like 1 is a novel neuroendocrine biomarker for prostate cancer
Prostate‑derived calcitonin (CT) and its receptor induce tumorigenicity and increase metastatic potential of prostate cancer (PC). CT‑inducible genes in human prostate were identified by subtraction hybridization. Among these genes, zinc finger protein like 1 (ZFPL1) protein was interesting since it was abundantly expressed in malignant prostates but was almost absent in benign prostates. ZFPL1 expression was upregulated by CT and androgens, and ZFPL1 protein was secreted by prostate tumor cells through exosomal secretion. Serum levels of ZFPL1 in cancer patients were at least 4‑fold higher than those in the sera of cancer‑free individuals. Cell biology of ZFPL1 suggests its localization in Golgi bodies and exosomes, and its colocalization with chromogranin A and CD44. These results suggested that ZFPL1 is secreted by tumor cells of neuroendocrine (NE)/stem cell phenotype. The knockdown of endogenous ZFPL1 in (PC) cells led to a remarkable decrease in cell proliferation, and invasion while increasing their apoptosis. As expected, the overexpression of ZFPL1 in prostate cells had an opposite effect on these functions. The knockdown of ZFPL1 in PC cells also decreased Akt phosphorylation, suggesting the actions of ZFPL1 may be mediated through the PI3K‑Akt pathway. Moreover, the present results revealed that ZFPL1 is released by tumors cells of NE or androgen‑independent phenotype and its serum levels are significantly higher in cancer patients, suggesting that it may serve as a blood‑based non‑invasive biomarker of aggressive PC.
- Open Access
- 12 January 2023
- Published by Impact Journals, LLC in Oncotarget
- Vol. 14  (1) , 316
Correction: Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis
- 12 January 2023
- Published by Impact Journals, LLC in Oncotarget
- Vol. 14  (1) , 316
Open AccessCorrection: Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis
- Open Access
- 11 November 2022
- Published by Springer Nature in Research Square
Androgens regulate CALCA gene expression in the prostate by methylation of CALCA Promoter
Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancer (PC), and activation of CT–CTR axis in non-invasive PC cells induces an invasive phenotype. However, the regulation of CT gene (CALCA) expression in the prostate has not been investigated. We investigated the regulation of CALCA gene expression in multiple PC cell lines and primary PC specimens. The results show that androgen-activated androgen receptor (AR) represses CALCA gene expression, and this can be abolished either by the knock-out of AR or the treatment with AR antagonists. Chromatin immunoprecipitation assay identified that AR induces methylation of CpG64 region of distal CALCA gene promoter, and this was prevented by knock-out of AR. This region was examined in multiple PC cell lines and primary PC specimens. PC cells that lacked CT mRNA abundance displayed methylated CpG64 region, and this methylation was partially reversed either with the knock-out of AR or incubation with AR antagonist. Primary prostate tissue specimens from normal or benign prostatic hyperplasia displayed methylated CALCA gene promoter. In contrast, those from advanced PCs displayed at least partially demethylated CALCA gene promoter. These results explain our earlier results that CALCA gene expression in the prostate is silent in benign prostate epithelium but is active in malignant prostate epithelium, and high level of CALCA gene expression in advanced PC. These results raise a possibility that elevated CALCA gene expression in malignant prostate may indicate progressive loss of AR expression and/or AR signaling.
- 11 November 2022
- Published by Springer Nature in Research Square
Open AccessAndrogens regulate CALCA gene expression in the prostate by methylation of CALCA Promoter
Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancer (PC), and activation of CT–CTR axis in non-invasive PC cells induces an invasive phenotype. However, the regulation of CT gene (CALCA) expression in the prostate has not been investigated. We investigated the regulation of CALCA gene expression in multiple PC cell lines and primary PC specimens. The results show that androgen-activated androgen receptor (AR) represses CALCA gene expression, and this can be abolished either by the knock-out of AR or the treatment with AR antagonists. Chromatin immunoprecipitation assay identified that AR induces methylation of CpG64 region of distal CALCA gene promoter, and this was prevented by knock-out of AR. This region was examined in multiple PC cell lines and primary PC specimens. PC cells that lacked CT mRNA abundance displayed methylated CpG64 region, and this methylation was partially reversed either with the knock-out of AR or incubation with AR antagonist. Primary prostate tissue specimens from normal or benign prostatic hyperplasia displayed methylated CALCA gene promoter. In contrast, those from advanced PCs displayed at least partially demethylated CALCA gene promoter. These results explain our earlier results that CALCA gene expression in the prostate is silent in benign prostate epithelium but is active in malignant prostate epithelium, and high level of CALCA gene expression in advanced PC. These results raise a possibility that elevated CALCA gene expression in malignant prostate may indicate progressive loss of AR expression and/or AR signaling.
- Open Access
- 3 March 2020
- Published by Impact Journals, LLC in Oncotarget
- Vol. 11  (9) , 858-874
Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ajay Kale1, Afaf Aldahish1 and Girish Shah1 1 Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71201, USA Correspondence to: Girish Shah, email: shah@ulm.edu Keywords: calcitonin receptor; T-antigen; tumor growth; PTEN; prostate cancer Received: November 26, 2019 Accepted: January 30, 2020 Published: March 03, 2020 ABSTRACT Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancer (PC) and activation of CT–CTR axis in non- invasive PC cells induces an invasive phenotype. However, the role of CT-CTR axis in prostate carcinogenesis has not been investigated. We employed a transgenic mouse prostate cancer model that uses long probasin promoter to target the expression of T-antigen in the prostate gland (LPB-Tag) along with CTR knock-out mice (CTRKO) to address this question. We cross-bred LPB-Tag mice with CTRKO to obtain four groups of mice. Prostates of these mice were obtained at the age of 90 days, fixed, paraffin-embedded, and used either for the extraction of RNA or for immunofluorescence. Prostate RNAs from different groups were reverse transcribed and used either for transcription profiling or for qRT-PCR. As expected, prostates of mice with LPB-Tag genotype displayed well-grown tumors with histologic features such as loss of normal morphology and nuclear atypia. WT as well as CTRKO mice displayed normal prostate morphology. Interestingly, LPB-Tag-CTRKO prostates also displayed relatively normal morphology which was indistinguishable from the WT. Microarray analysis as well as qRT-PCR suggested that CTRKO genotype reversed T-antigen-induced silencing of RB and PTEN gene expression as well as T-antigen-induced expression of several enzymes associated with lipid metabolism/ cholesterol biosynthesis, several cancer-related and androgen-regulated genes. The results for the first time identify mechanisms associated CTR-induced prostate carcinogenesis, and raise an exciting possibility of using a potent CT antagonist to attenuate progression of prostate cancer.
- 3 March 2020
- Published by Impact Journals, LLC in Oncotarget
- Vol. 11  (9) , 858-874
Open AccessCalcitonin receptor is required for T-antigen-induced prostate carcinogenesis
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Ajay Kale1, Afaf Aldahish1 and Girish Shah1 1 Pharmacology, University of Louisiana College of Pharmacy, Monroe, LA 71201, USA Correspondence to: Girish Shah, email: shah@ulm.edu Keywords: calcitonin receptor; T-antigen; tumor growth; PTEN; prostate cancer Received: November 26, 2019 Accepted: January 30, 2020 Published: March 03, 2020 ABSTRACT Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in prostate cancer (PC) and activation of CT–CTR axis in non- invasive PC cells induces an invasive phenotype. However, the role of CT-CTR axis in prostate carcinogenesis has not been investigated. We employed a transgenic mouse prostate cancer model that uses long probasin promoter to target the expression of T-antigen in the prostate gland (LPB-Tag) along with CTR knock-out mice (CTRKO) to address this question. We cross-bred LPB-Tag mice with CTRKO to obtain four groups of mice. Prostates of these mice were obtained at the age of 90 days, fixed, paraffin-embedded, and used either for the extraction of RNA or for immunofluorescence. Prostate RNAs from different groups were reverse transcribed and used either for transcription profiling or for qRT-PCR. As expected, prostates of mice with LPB-Tag genotype displayed well-grown tumors with histologic features such as loss of normal morphology and nuclear atypia. WT as well as CTRKO mice displayed normal prostate morphology. Interestingly, LPB-Tag-CTRKO prostates also displayed relatively normal morphology which was indistinguishable from the WT. Microarray analysis as well as qRT-PCR suggested that CTRKO genotype reversed T-antigen-induced silencing of RB and PTEN gene expression as well as T-antigen-induced expression of several enzymes associated with lipid metabolism/ cholesterol biosynthesis, several cancer-related and androgen-regulated genes. The results for the first time identify mechanisms associated CTR-induced prostate carcinogenesis, and raise an exciting possibility of using a potent CT antagonist to attenuate progression of prostate cancer.
- 1 November 2019
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 26  (11) , 815-828
Calcitonin induces stem cell-like phenotype in prostate cancer cells
Stem cell-like-cancer cells are key drivers of tumor growth, metastasis, and relapse of cancer following remission. Prostate stem cell-like cancer cells isolated from human prostate cancer (PC) biopsies express CD44+/α2β1 hi/CD133+ cell surface markers and can self-renew in vitro. Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in PCs and activation of CT-CTR axis in non-invasive PC cells induces an invasive phenotype. We investigated whether CT-CTR autocrine axis induces stem cell-like phenotype in two PC cell lines. CT-CTR axis in these cell lines was activated by enforced expression of CTR. The cells were then examined for the changes in the expression of CD44 and CD133, collagen adherence, tumorigenic, metastatic and repopulating characteristics. The activation of CT-CTR axis led to a large increase in adherence to collagen and a remarkable increase of CD44 and CD133 in PC-3 and LNCaP cells. This was accompanied by a strong increase in tumorigenic, metastatic and repopulation properties of PC cells. However, the mutation of CTR-C PDZ-binding site in CTR almost abolished CTR-mediated increases in stem cell-like characteristics of PC cells. These results support an important role for CT-CTR axis in the progression of PC from localized cancer to an aggressive form, and a majority of proinvasive CTR actions may be mediated through its interaction with its partner protein at the PDZ-binding site. These results suggest that CT/CTR can serve as a valuable target to prevent the generation of stem-like PC cells.
- 1 November 2019
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 26  (11) , 815-828
Calcitonin induces stem cell-like phenotype in prostate cancer cells
Stem cell-like-cancer cells are key drivers of tumor growth, metastasis, and relapse of cancer following remission. Prostate stem cell-like cancer cells isolated from human prostate cancer (PC) biopsies express CD44+/α2β1 hi/CD133+ cell surface markers and can self-renew in vitro. Expression of calcitonin (CT) and its receptor (CTR) is frequently elevated in PCs and activation of CT-CTR axis in non-invasive PC cells induces an invasive phenotype. We investigated whether CT-CTR autocrine axis induces stem cell-like phenotype in two PC cell lines. CT-CTR axis in these cell lines was activated by enforced expression of CTR. The cells were then examined for the changes in the expression of CD44 and CD133, collagen adherence, tumorigenic, metastatic and repopulating characteristics. The activation of CT-CTR axis led to a large increase in adherence to collagen and a remarkable increase of CD44 and CD133 in PC-3 and LNCaP cells. This was accompanied by a strong increase in tumorigenic, metastatic and repopulation properties of PC cells. However, the mutation of CTR-C PDZ-binding site in CTR almost abolished CTR-mediated increases in stem cell-like characteristics of PC cells. These results support an important role for CT-CTR axis in the progression of PC from localized cancer to an aggressive form, and a majority of proinvasive CTR actions may be mediated through its interaction with its partner protein at the PDZ-binding site. These results suggest that CT/CTR can serve as a valuable target to prevent the generation of stem-like PC cells.
- 1 August 2017
- Published by Elsevier in Cellular Signalling
- Vol. 36, 1-13
Calcitonin receptor increases invasion of prostate cancer cells by recruiting zonula occludens-1 and promoting PKA-mediated TJ disassembly
- 1 August 2017
- Published by Elsevier in Cellular Signalling
- Vol. 36, 1-13
Calcitonin receptor increases invasion of prostate cancer cells by recruiting zonula occludens-1 and promoting PKA-mediated TJ disassembly
- Open Access
- 2 March 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11  (3) , e0150090
Calcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis
The role of neuroendocrine peptide calcitonin (CT) and its receptor (CTR) in epithelial cancer progression is an emerging concept with great clinical potential. Expression of CT and CTR is frequently elevated in prostate cancers (PCs) and activation of CT–CTR axis in non-invasive PC cells induces an invasive phenotype. Here we show by yeast-two hybrid screens that CTR associates with the tight junction protein Zonula Occludens-1 (ZO-1) via the interaction between the type 1 PDZ motif at the carboxy-terminus of CTR and the PDZ3 domain of ZO-1. Mutation of either the CTR C-PDZ-binding motif or the ZO-1-PDZ3 domain did not affect binding of CTR with its ligand or G-protein-mediated signaling but abrogated destabilizing actions of CT on tight junctions and formation of distant metastases by orthotopically implanted PC cells in nude mice, indicating that these PDZ domain interactions were pathologically relevant. Further, we observed CTR-ZO-1 interactions in PC specimens by proximity ligation immunohistochemistry, and identified that the number of interactions in metastatic PC specimens was several-fold larger than in non-metastatic PC. Our results for the first time demonstrate a mechanism by which PDZ-mediated interaction between CTR and ZO1 is required for CT-stimulated metastasis of prostate cancer. Since many receptors contain PDZ-binding motifs, this would suggest that PDZ-binding motif-adaptor protein interactions constitute a common mechanism for cancer metastasis.
- 2 March 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11  (3) , e0150090
Open AccessCalcitonin Receptor-Zonula Occludens-1 Interaction Is Critical for Calcitonin-Stimulated Prostate Cancer Metastasis
The role of neuroendocrine peptide calcitonin (CT) and its receptor (CTR) in epithelial cancer progression is an emerging concept with great clinical potential. Expression of CT and CTR is frequently elevated in prostate cancers (PCs) and activation of CT–CTR axis in non-invasive PC cells induces an invasive phenotype. Here we show by yeast-two hybrid screens that CTR associates with the tight junction protein Zonula Occludens-1 (ZO-1) via the interaction between the type 1 PDZ motif at the carboxy-terminus of CTR and the PDZ3 domain of ZO-1. Mutation of either the CTR C-PDZ-binding motif or the ZO-1-PDZ3 domain did not affect binding of CTR with its ligand or G-protein-mediated signaling but abrogated destabilizing actions of CT on tight junctions and formation of distant metastases by orthotopically implanted PC cells in nude mice, indicating that these PDZ domain interactions were pathologically relevant. Further, we observed CTR-ZO-1 interactions in PC specimens by proximity ligation immunohistochemistry, and identified that the number of interactions in metastatic PC specimens was several-fold larger than in non-metastatic PC. Our results for the first time demonstrate a mechanism by which PDZ-mediated interaction between CTR and ZO1 is required for CT-stimulated metastasis of prostate cancer. Since many receptors contain PDZ-binding motifs, this would suggest that PDZ-binding motif-adaptor protein interactions constitute a common mechanism for cancer metastasis.
- 1 March 2016
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 77, 491-498
Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip
- 1 March 2016
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 77, 491-498
Measurement of serum prostate cancer markers using a nanopore thin film based optofluidic chip